{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:40:49Z","timestamp":1791196849407,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1038\/nrrheum.2009.184","type":"journal-article","created":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T11:37:16Z","timestamp":1254397036000},"page":"572-577","source":"Crossref","is-referenced-by-count":177,"title":["CD19: a promising B cell target for rheumatoid arthritis"],"prefix":"10.1038","volume":"5","author":[{"given":"Thomas F.","family":"Tedder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrrheum2009184_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","volume":"112","author":"TW LeBien","year":"2008","unstructured":"LeBien, T. W. & Tedder, T. F. B-lymphocytes: how they develop and function. Blood 112, 1570\u20131580 (2008).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR2","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572\u20132581 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009184_CR3","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.4049\/jimmunol.179.2.1369","volume":"179","author":"K Yanaba","year":"2007","unstructured":"Yanaba, K. et al. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179, 1369\u20131380 (2007).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR4","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.4049\/jimmunol.180.7.4994","volume":"180","author":"K Hamel","year":"2008","unstructured":"Hamel, K. et al. Suppression of proteoglycan-induced arthritis by anti-CD20 B cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J. Immunol. 180, 4994\u20135003 (2008).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","volume":"15","author":"TF Tedder","year":"1994","unstructured":"Tedder, T. F. & Engel, P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15, 450\u2013454 (1994).","journal-title":"Immunol. Today"},{"key":"BFnrrheum2009184_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JCW Edwards","year":"2001","unstructured":"Edwards, J. C. W. & Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40, 205\u2013211 (2001).","journal-title":"Rheumatology"},{"key":"BFnrrheum2009184_CR7","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1002\/art.10541","volume":"46","author":"MJ Leandro","year":"2002","unstructured":"Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosis. Arthritis Rheum. 46, 2673\u20132677 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009184_CR8","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.10947","volume":"48","author":"GJ Silverman","year":"2002","unstructured":"Silverman, G. J. & Weisman, S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48, 1484\u20131492 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009184_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676\u2013688 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009184_CR10","doi-asserted-by":"publisher","first-page":"20882","DOI":"10.1073\/pnas.0709205105","volume":"104","author":"JD Bouaziz","year":"2007","unstructured":"Bouaziz, J. D. et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc. Natl Acad. Sci. USA 104, 20882\u201320887 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2009184_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1600-065X.2008.00646.x","volume":"223","author":"K Yanaba","year":"2008","unstructured":"Yanaba, K. et al. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223, 284\u2013299 (2008).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum2009184_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaci.2007.11.030","volume":"121","author":"MC Levesque","year":"2008","unstructured":"Levesque, M. C. & St Clair, E. W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol. 121, 13\u201321 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrrheum2009184_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","volume":"20","author":"RP Taylor","year":"2008","unstructured":"Taylor, R. P. & Lindorfer, M. A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20, 444\u2013449 (2008).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum2009184_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","volume":"180","author":"DJ DiLillo","year":"2008","unstructured":"DiLillo, D. J. et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180, 361\u2013371 (2008).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR15","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson, K. C. et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63, 1424\u20131433 (1984).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood.V70.5.1316.1316","volume":"70","author":"MR Loken","year":"1987","unstructured":"Loken, M. R., Shah, V. O., Dattilio, K. L. & Civin, C. I. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 70, 1316\u20131324 (1987).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","volume":"71","author":"FM Uckun","year":"1988","unstructured":"Uckun, F. M. et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71, 13\u201329 (1988).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR18","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.V76.9.1739.1739","volume":"76","author":"LW Terstappen","year":"1990","unstructured":"Terstappen, L. W., Johnsen, S., Segers-Nolten, I. M. & Loken, M. R. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 76, 1739\u20131747 (1990).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","volume":"131","author":"LM Nadler","year":"1983","unstructured":"Nadler, L. M. et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen activated, and malignant B lymphocytes. J. Immunol. 131, 244\u2013250 (1983).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/10428199509059636","volume":"18","author":"RH Scheuermann","year":"1995","unstructured":"Scheuermann, R. H. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk. Lymphoma 18, 385\u2013397 (1995).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrrheum2009184_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","volume":"6","author":"TF Tedder","year":"1997","unstructured":"Tedder, T. F., Inaoki, M. & Sato, S. The CD19\/21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6, 107\u2013118 (1997).","journal-title":"Immunity"},{"key":"BFnrrheum2009184_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1074-7613(00)00007-8","volume":"13","author":"M Fujimoto","year":"2000","unstructured":"Fujimoto, M. et al. CD19 regulates Src-family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13, 47\u201357 (2000).","journal-title":"Immunity"},{"key":"BFnrrheum2009184_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/1074-7613(95)90157-4","volume":"3","author":"P Engel","year":"1995","unstructured":"Engel, P. et al. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3, 39\u201350 (1995).","journal-title":"Immunity"},{"key":"BFnrrheum2009184_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/376352a0","volume":"376","author":"RC Rickert","year":"1995","unstructured":"Rickert, R. C., Rajewsky, K. & Roes, J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376, 352\u2013355 (1995).","journal-title":"Nature"},{"key":"BFnrrheum2009184_CR25","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa051568","volume":"354","author":"MC van Zelm","year":"2006","unstructured":"van Zelm, M. C. et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354, 1901\u20131912 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009184_CR26","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1084\/jem.186.11.1923","volume":"186","author":"M Inaoki","year":"1997","unstructured":"Inaoki, M., Sato, S., Weintraub, B. C., Goodnow, C. C. & Tedder, T. F. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J. Exp. Med. 186, 1923\u20131931 (1997).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2009184_CR27","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.4049\/jimmunol.157.10.4371","volume":"157","author":"S Sato","year":"1996","unstructured":"Sato, S., Ono, N., Steeber, D. A., Pisetsky, D. S. & Tedder, T. F. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157, 4371\u20134378 (1996).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR28","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","volume":"165","author":"S Sato","year":"2000","unstructured":"Sato, S., Hasegawa, M., Fujimoto, M., Tedder, T. F. & Takehara, K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165, 6635\u20136643 (2000).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR29","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1002\/art.20674","volume":"50","author":"N Tsuchiya","year":"2004","unstructured":"Tsuchiya, N. et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis (scleroderma). Arthritis Rheum. 50, 4002\u20134007 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009184_CR30","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.4049\/jimmunol.167.5.2469","volume":"167","author":"M Hasegawa","year":"2001","unstructured":"Hasegawa, M. et al. A CD19-dependent signaling pathway regulates autoimmunity in Lyn-deficient mice. J. Immunol. 167, 2469\u20132478 (2001).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/0167-5699(90)90160-B","volume":"11","author":"J Westermann","year":"1991","unstructured":"Westermann, J. & Pabst, R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol. Today 11, 406\u2013410 (1991).","journal-title":"Immunol. Today"},{"key":"BFnrrheum2009184_CR32","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1084\/jem.20040119","volume":"199","author":"J Uchida","year":"2004","unstructured":"Uchida, J. et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659\u20131669 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2009184_CR33","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.4049\/jimmunol.174.7.4389","volume":"174","author":"Y Hamaguchi","year":"2005","unstructured":"Hamaguchi, Y. et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174, 4389\u20134399 (2005).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR34","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","volume":"174","author":"Q Gong","year":"2005","unstructured":"Gong, Q. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817\u2013826 (2005).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR35","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1128\/MCB.14.6.3884","volume":"14","author":"L-J Zhou","year":"1994","unstructured":"Zhou, L.-J. et al. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B lymphocyte development. Mol. Cell. Biol. 14, 3884\u20133894 (1994).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrrheum2009184_CR36","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.4049\/jimmunol.158.10.4662","volume":"158","author":"S Sato","year":"1997","unstructured":"Sato, S., Steeber, D. A., Jansen, P. J. & Tedder, T. F. CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. J. Immunol. 158, 4662\u20134669 (1997).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR37","doi-asserted-by":"publisher","first-page":"15178","DOI":"10.1073\/pnas.0505539102","volume":"102","author":"N Yazawa","year":"2005","unstructured":"Yazawa, N., Hamaguchi, Y., Poe, J. C. & Tedder, T. F. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl Acad. Sci. USA 102, 15178\u201315183 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2009184_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ajh.2830400404","volume":"40","author":"NM Almasri","year":"1992","unstructured":"Almasri, N. M., Duque, R. E., Iturraspe, J., Everett, E. & Braylan, R. C. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am. J. Hematol. 40, 259\u2013263 (1992).","journal-title":"Am. J. Hematol."},{"key":"BFnrrheum2009184_CR39","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","volume":"81","author":"H Harada","year":"1993","unstructured":"Harada, H. et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81, 2658\u20132663 (1993).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","volume":"169","author":"M Hasegawa","year":"2006","unstructured":"Hasegawa, M. et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol. 169, 954\u2013966 (2006).","journal-title":"Am. J. Pathol."},{"key":"BFnrrheum2009184_CR41","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","volume":"68","author":"HM Horton","year":"2008","unstructured":"Horton, H. M. et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 68, 8049\u20138057 (2008).","journal-title":"Cancer Res."},{"key":"BFnrrheum2009184_CR42","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood-2008-10-182048","volume":"113","author":"J Zalevsky","year":"2009","unstructured":"Zalevsky, J. et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fc\u03b3 receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113, 3735\u20133743 (2009).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR43","first-page":"351","volume":"28","author":"TF Tedder","year":"2006","unstructured":"Tedder, T. F., Baras, A. & Xiu, Y. Fc\u03b3 receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Sem. Pathol. 28, 351\u2013364 (2006).","journal-title":"Sem. Pathol."},{"key":"BFnrrheum2009184_CR44","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF01741331","volume":"32","author":"A Hekman","year":"1991","unstructured":"Hekman, A. et al. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol. Immunother. 32, 364\u2013372 (1991).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrrheum2009184_CR45","first-page":"37","volume":"40","author":"LT Vlasveld","year":"1995","unstructured":"Vlasveld, L. T. et al. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol. Immunother. 40, 37\u201347 (1995).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrrheum2009184_CR46","first-page":"2392","volume":"5","author":"ML Grossbard","year":"1999","unstructured":"Grossbard, M. L. et al. A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 2392\u20132398 (1999).","journal-title":"Clin. Cancer Res."},{"key":"BFnrrheum2009184_CR47","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.4049\/jimmunol.147.12.4094","volume":"147","author":"GS Kansas","year":"1991","unstructured":"Kansas, G. S. & Tedder, T. F. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J. Immunol. 147, 4094\u20134102 (1991).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR48","first-page":"483","volume-title":"Leukocyte Typing V: White Cell Differentiation Antigens","author":"TF Tedder","year":"1995","unstructured":"Tedder, T. F., Wagner, N. & Engel, P. in Leukocyte Typing V: White Cell Differentiation Antigens Vol. 1. (eds Schlossman, S. F. et al.) 483\u2013504 (Oxford University Press, Oxford, UK, 1995)."},{"key":"BFnrrheum2009184_CR49","doi-asserted-by":"crossref","first-page":"50.16","DOI":"10.4049\/jimmunol.182.Supp.50.16","volume":"182","author":"S Gallagher","year":"2009","unstructured":"Gallagher, S. et al. Macrophages are required for anti-CD19 mAb mediated B cell depletion in mice. J. Immunol. 182, 50.16 (2009).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009184_CR50","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson, K. R. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113, 4834\u20134840 (2009).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR51","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1002\/art.22657","volume":"56","author":"LH Calabrese","year":"2007","unstructured":"Calabrese, L. H., Molloy, E. S., Huang, D. & Ransohoff, R. M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 56, 2116\u20132128 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009184_CR52","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.immuni.2008.03.017","volume":"28","author":"K Yanaba","year":"2008","unstructured":"Yanaba, K. et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639\u2013650 (2008).","journal-title":"Immunity"},{"key":"BFnrrheum2009184_CR53","first-page":"3420","volume":"118","author":"T Matsushita","year":"2008","unstructured":"Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420\u20133430 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum2009184_CR54","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/ibd.20215","volume":"13","author":"M Goetz","year":"2007","unstructured":"Goetz, M., Atreya, R., Ghalibafian, M., Galle, P. R. & Neurath, M. F. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis. 13, 1365\u20131368 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrrheum2009184_CR55","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1002\/art.22811","volume":"56","author":"S Dass","year":"2007","unstructured":"Dass, S., Vital, E. M. & Emery, P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56, 2715\u20132718 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009184_CR56","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/archneur.64.10.1531","volume":"64","author":"L Benedetti","year":"2007","unstructured":"Benedetti, L. et al. Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. Arch. Neurol. 64, 1531\u20131533 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrrheum2009184_CR57","first-page":"4906","volume":"49","author":"OW Press","year":"1989","unstructured":"Press, O. W., Farr, A. G., Borroz, K. I., Anderson, S. K. & Martin, P. J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 49, 4906\u20134912 (1989).","journal-title":"Cancer Res."},{"key":"BFnrrheum2009184_CR58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V77.4.787.787","volume":"77","author":"F Schriever","year":"1991","unstructured":"Schriever, F., Freeman, G. & Nadler, L. M. Follicular dendritic cells contain a unique gene repertoire demonstrated by single-cell polymerase chain reaction. Blood 77, 787\u2013791 (1991).","journal-title":"Blood"},{"key":"BFnrrheum2009184_CR59","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.V83.5.1329.1329","volume":"83","author":"M-A Ghetie","year":"1994","unstructured":"Ghetie, M.-A. et al. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 83, 1329\u20131336 (1994).","journal-title":"Blood"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2009.184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2009.184","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2009.184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T20:36:14Z","timestamp":1685133374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2009.184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["BFnrrheum2009184"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2009.184","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}